EIDXUnknown
Eidos Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Eidos Therapeutics, Inc. (EIDX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are EIDX insiders buying or selling?
Eidos Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2018, Trabud has recorded 73 Form 4 filings for EIDX: 19 buys ($352.9M) and 54 sells ($25.6M).
Source: SEC EDGAR Form 4
Key Statistics (June 2018 – Jan 26, 2021)
Total Form 4 filings
73
SEC EDGAR
Insider filers
11
Insider buys (19)
$352.9M
Insider sells (54)
$25.6M
Insider sentiment
Net buyingNet insider flow of $327.3M in net buying since June 2018.
Recent EIDX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 26, 2021 | BridgeBio Pharma, Inc. | 10% Owner | Purchase | 14.4M | $0.00 | $0 | SEC ↗ |
| Jan 15, 2021 | Uma Sinha | Chief Scientific Officer | Sale | 10.0K | $124.32 | $1.2M | SEC ↗ |
| Jan 13, 2021 | Franco Valle | Senior Vice President, Finance | Sale | 3.2K | $125.52 | $407.6K | SEC ↗ |
| Dec 17, 2020 | Cameron Turtle | Chief Business Officer | Sale | 26.3K | $111.77 | $2.9M | SEC ↗ |
| Dec 4, 2020 | Uma Sinha | Chief Scientific Officer | Sale | 5.0K | $90.04 | $450.2K | SEC ↗ |
| Nov 13, 2020 | Cameron Turtle | Chief Business Officer | Sale | 13.4K | $74.51 | $999.2K | SEC ↗ |
| Nov 10, 2020 | Franco Valle | Senior Vice President, Finance | Sale | 1.6K | $74.93 | $121.6K | SEC ↗ |
| Nov 3, 2020 | Cameron Turtle | Chief Business Officer | Sale | 12.5K | $70.72 | $884.0K | SEC ↗ |
| Oct 30, 2020 | Uma Sinha | Chief Scientific Officer | Sale | 5.0K | $72.42 | $362.1K | SEC ↗ |
| Oct 9, 2020 | Franco Valle | Senior Vice President, Finance | Sale | 10.6K | $74.97 | $797.9K | SEC ↗ |
| Oct 2, 2020 | Uma Sinha | Chief Scientific Officer | Sale | 5.0K | $52.34 | $261.7K | SEC ↗ |
| Sep 18, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 5.8K | $50.16 | $289.3K | SEC ↗ |
| Sep 16, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 4.2K | $50.14 | $212.2K | SEC ↗ |
| Sep 11, 2020 | Cameron Turtle | Chief Business Officer | Sale | 2.5K | $47.00 | $117.5K | SEC ↗ |
| Aug 5, 2020 | Cameron Turtle | Chief Business Officer | Sale | 10.0K | $39.95 | $399.4K | SEC ↗ |
| Jul 9, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 5.0K | $50.00 | $250.0K | SEC ↗ |
| Jun 5, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 5.0K | $50.00 | $250.0K | SEC ↗ |
| Jun 1, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 5.0K | $50.00 | $250.0K | SEC ↗ |
| May 28, 2020 | Cameron Turtle | Chief Business Officer | Sale | 2.5K | $47.00 | $117.5K | SEC ↗ |
| May 5, 2020 | Cameron Turtle | Chief Business Officer | Sale | 10.0K | $40.84 | $408.4K | SEC ↗ |
| Apr 27, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 5.0K | $50.00 | $250.0K | SEC ↗ |
| Apr 22, 2020 | Franco Valle | Senior Vice President, Finance | Sale | 2.0K | $49.79 | $99.6K | SEC ↗ |
| Mar 30, 2020 | Franco Valle | Senior Vice President, Finance | Sale | 5.0K | $48.26 | $241.3K | SEC ↗ |
| Mar 4, 2020 | Franco Valle | Senior Vice President, Finance | Sale | 3.0K | $52.33 | $157.0K | SEC ↗ |
| Mar 4, 2020 | Jonathan C Fox | President and Chief Medical Officer | Sale | 10.0K | $51.57 | $515.7K | SEC ↗ |
Showing the 25 most recent of 73 Form 4 filings for Eidos Therapeutics, Inc..
Most active EIDX insiders
- Jonathan C Fox21 filings
- Cameron Turtle12 filings
- BridgeBio Pharma, Inc.9 filings
- Uma Sinha8 filings
- Christine Siu7 filings
Ask anything about EIDX insider activity
Use Trabud's AI agent to query Eidos Therapeutics, Inc.'s Form 4 history in plain English — "Show me EIDX CEO purchases this year" or compare it against any other ticker.
Open the AI agentEIDX insider trading FAQ
Are Eidos Therapeutics, Inc. insiders buying or selling?
Eidos Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2018, Trabud has recorded 73 Form 4 filings for EIDX: 19 buys ($352.9M) and 54 sells ($25.6M). Over the full record that is net buying of $327.3M.
How many insiders trade EIDX stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Eidos Therapeutics, Inc.. The most recent filing was accepted on Jan 26, 2021.
Where does Trabud get EIDX insider trading data?
All EIDX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.